Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated‐interferon and ribavirin. Issue 1 (January 2014)

• Record Type: Journal Article
• Authors: Hai, Hoang; Tamori, Akihiro; Enomoto, Masaru; Morikawa, Hiroyasu; Uchida‐Kobayashi, Sawako; Fujii, Hideki; Hagihara, Atsushi; Kawamura, Etsushi; Thuy, Le Thi Thanh; Tanaka, Yasuhito; Kawada, Norifumi
• Is Part Of: Journal of gastroenterology and hepatology. Volume 29:Issue 1(2014:Jan.)
• Page Start: 201
• Page End: 207
• Publication Date: 2014-01
• Subjects: Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.12376
• Languages: English
• ISSNs: 0815-9319

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="jgh12376-sec-0001" sec-type="section"> <title>Background and Aim</title> <p>It is not yet clear which factors are associated with the outcome of 72‐week treatment with pegylated‐interferon and ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection.</p> </sec> <sec id="jgh12376-sec-0002" sec-type="section"> <title>Methods</title> <p>In 66 patients with HCV genotype 1 who had a late viral response (LVR) to 72‐week treatment of pegylated‐interferon and RBV, we examined the factors that determined the outcome, including single nucleotide polymorphisms of interleukin‐28B and inosine triphosphatase (<italic>ITPA</italic>) genes.</p> </sec> <sec id="jgh12376-sec-0003" sec-type="section"> <title>Results</title> <p>Thirty seven of 66 (56%) patients with LVR achieved a sustained viral response (SVR). The mean age of these 37 SVR patients was 55, compared with 61 in 29 relapsed patients (<italic>P</italic> = 0.009). Twenty six of 54 (48%) patients with the CC genotype and 11 of 12 (92%) with the CA/AA genotype of <italic>ITPA</italic> rs1127354 achieved SVR (<italic>P</italic> = 0.006). The SVR rates were 79%, 40%, 60%, and 33% in patients with undetectable HCV RNA on weeks 16, 20, 24, and 28 or later, respectively (<italic>P</italic> = 0.014). Finally, serum RBV concentration at week 44 of treatment was significantly higher in the SVR group (2651 ng/mL) than in the relapse group (1989 ng/mL, <italic>P</italic> = 0.002). In contrast, the rate of the interleukin‐28B genotype was not different between the groups. Multiple regression analysis showed that age < 60 years, <italic>ITPA</italic> CA/AA genotype, and serum RBV concentration were significant independent predictive factors for SVR.</p> </sec> <sec id="jgh12376-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Our findings elucidated the association of four factors, including <italic>ITPA</italic> genotype, with the outcome of 72‐week treatment in LVR patients.</p> </sec> </abstract>